Specialty Pharmacy

The Patient Navigator Program reduced readmission for heart attack or heart failure patients by 81.3%.

The PCSK9 inhibitor dramatically reduces high cholesterol and cuts the risk of heart attack and stroke.

The Blueprint for Transparency at the FDA provides 18 recommendations for the release of regulatory information and data.

Study is the first to examine the function of SP140 protein in inflammatory diseases.

Insulin could become a new therapeutic option for HIV-associated neurocognitive disorders.

Autumn Bagwell, PharmD, BCPS, clinical pharmacist at Vanderbilt Specialty Pharmacy, discusses methods pharmacists can employ to maintain adherence.

Top news of the day from across the health care landscape.

A combination drug regimen may be the answer to treating acute myeloid leukemia.

Evolocumab offers a 25% reduction in cardiovascular (CV) death, heart attack, or stroke after the first year.

Small case report found an association between the Zika virus and cardiovascular complications.

FOURIER trial meets its primary composite endpoint reducing cardiovascular risk factors.

Mylan gains global licenses for its biosimilar to trastuzumab (Herceptin).

Senescent cells communication via integrin beta 3 expression.

Daniel P. Kus, BS Pharm, RPh, vice president, Pharmacy Advantage, discusses key quality measures that define successful specialty pharmacies.

ATR mutations increase skin cancer tumor growth by modulating the tumor microenvironment.

Some high-risk patients have better than expected outcomes due to frequent follow-up by physicians.

Top news of the day from across the health care landscape.

Clinicians should screen all newly diagnosed HIV patients for tuberculosis.

Improvements in breast cancer patient quality of life and mortality seen over last 30 years.

Heart failure higher among RA patients independent of their risk for ischemic heart disease.

Hypertension can cause cardiovascular risk factors in patients with HIV.

New MS diagnoses are steadily on the rise.

Scientists discover a metabolic weakness in advanced breast cancer cells.

High genomic copy loss correlated with metastatic melanoma’s ability to thwart the success of immune checkpoint inhibitors.

Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.

Top news of the day from across the health care landscape.

The study from Sweden found a substantial benefit for men taking the class of drugs that was discovered by accident when researchers were developing a treatment for angina 2 decades ago.

The study finds that this biomarker can show which patients may develop heart disease even if they have no current blockage or elevated cholesterol levels.